US pharmaceutical major Eli Lilly on Wednesday launched its blockbuster diabetes drug Mounjaro in KwikPen, a single patient use prefilled pen designed for once weekly administration-in the Indian market, intensifying competition with rival Danish drugmarker Novo Nordisk. The pen will be available in six dose strengths and the price starts from Rs 14,000 for 2.5…
Lupin unveils Glucagon for Injection for severe hypoglycemia in patients with diabetes mellitus in US We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Mounjaro, Wegovy sales in India double on month in July We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Orforglipron Shows Significant Weight Loss and Heart Health Benefits in Phase 3 Trial We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
US drugmaker Eli Lilly‘s weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country’s fastest-growing prescription brands ever by value. The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If…
Eli Lilly’s investigational obesity pill led to less weight loss in a late-stage trial than the reductions seen with injectable treatments on the market, results that weaken its competitiveness as one of Lilly’s most-anticipated candidates. After 72 weeks, patients taking the highest dose of the therapy, called orforglipron, experienced 11.2% weight loss, when analyzing all…
Eli Lilly expands India presence with inauguration of Hyderabad site We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link